HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.0%

Neg 0% Neu 88% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.